ArticleFrontiers in immunology2026
Intrathecal IgG synthesis as a biomarker for CNS involvement in anti-GQ1b antibody syndrome: a case report and hypothesis-generating treatment framework.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-GQ1b antibody syndromes span a clinical continuum from peripheral Guillain-Barré syndrome (GBS) to central Bickerstaff brainstem encephalitis (BBE), but reliable biomarkers of central nervous system (CNS) involvement that could guide treatment intensity are lacking. We report a 37-year-old woman with a relapsing GBS-Miller Fisher syndrome (MFS)-BBE overlap phenotype. In the first episode (March 2024), plasma exchange, intravenous methylprednisolone and IVIG were administered after anti-GD1a IgG was detected. After self-discontinuation of immunotherapy, she was readmitted in May 2024 with a two-month course of progressive weakness acutely worsened over four days, ophthalmoplegia, dysarthria, intermittent choking and bilateral extensor plantar responses. CSF showed albuminocytologic dissociation (protein 2.21 g/L; total cell count 40×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.